Login to Your Account

Heat seeks spark in checkpoint inhibitors

By Michael Fitzhugh
Staff Writer

Tuesday, September 1, 2015

Heat Biologics Inc. is winding down a phase II study of its injectable adenocarcinoma cell vaccine, HS-110, in combination with low-dose cyclophosphamide, to focus instead on the potential benefits of combining the vaccine with Opdivo to battle NSCLC.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription